ISCO - International Stem Cell Corporation
| Previous Close | 0.7100 |
| Open | 0.7000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.7000 - 0.7000 |
| 52 Week Range | 0.6800 - 1.9000 |
| Volume | 3,300 |
| Avg. Volume | 3,521 |
| Market Cap | 5.273M |
| Beta (3Y Monthly) | 0.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3290 |
| Earnings Date | Nov 13, 2019 - Nov 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.54 |
- GlobeNewswire
International Stem Cell Corporation Announces Operating Results for the Quarter Ended March 31, 2019
CARLSBAD, Calif., May 17, 2019 -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage.
- GlobeNewswire
International Stem Cell Corporation is Valued at $43 Million Market Value by Edison Investment Research
CARLSBAD, Calif., May 08, 2019 -- International Stem Cell Corporation (OTCQB:ISCO) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing.
- GlobeNewswire
International Stem Cell Corporation Completes Enrollment and Dosing in its Parkinson's Disease Clinical Trial
International Stem Cell Corporation (ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today the completion of subject enrollment in its phase 1 clinical trial of ISC-hpNSC® for the treatment of Parkinson’s disease. The fourth subject of the third cohort, who was the twelfth and final subject of the phase 1 clinical study, was successfully transplanted with the highest dose of ISC-hpNSC® cells. This clinical trial, which involved 12 patients with Parkinson’s disease, was conducted in collaboration with investigators from Royal Melbourne Hospital, a leading medical institution with an international reputation for excellence.
- GlobeNewswire
International Stem Cell Corporation Announces 2018 Fourth Quarter and Year-End Results
CARLSBAD, Calif., April 15, 2019 -- International Stem Cell Corporation (OTCQX: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical.
- PR Newswire
OTC Markets Group Welcomes International Stem Cell Corporation to OTCQX
NEW YORK , March 4, 2019 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced International Stem Cell Corporation ...
- GlobeNewswire
International Stem Cell Corporation Commences Trading on the OTCQX Best Market
CARLSBAD, Calif., March 04, 2019 -- International Stem Cell Corporation (OTCQX:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical.
- GlobeNewswire
International Stem Cell Corporation Publishes Successful Results in Traumatic Brain Injury
CARLSBAD, Calif., Feb. 13, 2019 -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage.
- GlobeNewswire
International Stem Cell Corporation Granted Key US Patent Protecting Anti-Aging Business
CARLSBAD, Calif., Jan. 15, 2019 -- International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based, clinical.
- GlobeNewswire
Edison issues update on International Stem Cell (ISCO)
LONDON, Dec. 04, 2018 -- International Stem Cell (ISCO) reported Q318 revenues of $3.2m, up 73.0% compared to Q317 mainly due to the biomedical business, which had quarterly.
- GlobeNewswire
International Stem Cell Corporation Announces Strong Financial Results for the Three and Nine-Months ended September 30, 2018
Increases in Revenues and Profit MarginsNet Income Realized for the Quarter CARLSBAD, Calif., Nov. 15, 2018 -- International Stem Cell Corporation (OTCQB:ISCO).
- GlobeNewswire
International Stem Cell Corporation Announces Positive Top-Line Preliminary Results from Parkinson’s Disease Clinical Trial
International Stem Cell Corporation (ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today positive 12-month results of the first cohort and six-month interim results of the second cohort of its currently-ongoing, single-arm, open-label phase 1 clinical study (NCT02452723) evaluating the safety and tolerability of its lead candidate, ISC-hpNSC®, a cellular therapeutic consisting of human parthenogenetic neural stem cells, for the treatment of Parkinson’s disease (PD).
- GlobeNewswire
International Stem Cell Corporation to Present Clinical Data at the Society for Neuroscience Annual Meeting
International Stem Cell Corporation (ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today it will present at the Society for Neuroscience Annual Meeting (Neuroscience 2018), being held November 3-7, 2018 in San Diego, CA. ISCO’s presentation, titled, “Results of the first cohort of an open label dose escalating phase 1 study evaluating the safety of a human neural stem cell-based therapy in Parkinson’s disease,” will primarily focus on interim data received in its currently-ongoing Phase I clinical study of its lead candidate, ISC-hpNSC®, for the treatment of Parkinson's disease.